krystexxa

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) has its Overweight rating reiterated by JP Morgan following the Tuesday (9/14) evening announcement that the FDA has approved Krystexxa for the treatment of gout, JP Morgan reports, and the focus is expected to turn to the company's strategies concerning...